Facilitating NHS adoption of ATMPs
CGT Catapult coordinates the Advanced Therapy Treatment Centres (ATTC), a network of centres operating within the NHS framework dedicated to improving patient access to ATMPs across the UK.
Recognising that the adoption of ATMPs into healthcare systems was posing barriers to patient access, the Cell and Gene Therapy Catapult established the ATTC network to streamline and address the challenges of bringing innovative cell and gene therapies into routine medical practise.
Established in 2018 with funding through UK Research and Innovation (UKRI), the ATTC network was set up as a world first; operating within the NHS framework to develop systems and procedures to introduce ATMPs into the clinic and establish them as a standard of care.
Since its inception, the ATTC network has worked with the NHS and industry to devise systems to accelerate the NHS’ abilities to deliver advanced therapies to patients; identifying and overcoming barriers to adoption and developing resources and ways of working within and across NHS centres to support the increased clinical use of ATMPs.
CGT Catapult continues to provide coordination of the network as it focuses on accelerating ATMP clinical trials in the UK, under a £17.9m strategic initiative funded by the National Institute for Health and Care Research (NIHR) and supported by Innovate UK.
Working on a cell or gene therapy innovation challenge?
Contact us today to find out how we can support you.